AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06562998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline 400mg twice daily plus paclitaxel based regimens for 12weeks.
Study NCT04946344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet & Exercise
Description: Participants will attend exercise and diet classes.
Study NCT04946344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants will attend healthy living classes and receive phone calls/emails/texts.
Study NCT06562998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Pentoxifylline 400mg twice daily plus paclitaxel based regimens for 12weeks.
Study NCT05031260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: applying COMORAL®
Description: The individuals in the experimental group will be asked to come to the clinic to use COMORAL® three times a day, every day except Saturday and Sunday.
Study NCT05123105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1) cupping therapy
Description: The participant lay on his front on a couch. The examiner applied a plastic cup on a pre-marked trigger point, suctioned it with a mechanical pump and left it for 2 minutes. This was a stationary application with medium suction force. Therapy was performed on both sides. Measurements were taken before and 2 minutes after the therapy.
Study NCT05123105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2) control test (no intervention)
Description: The participant lay on his front on a couch for 4 minutes without any activity and without anyy intervention. Measurements were taken before and after the session.
Study NCT05123105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3) ischemic compression
Description: The participant lay on his front on a couch. The researcher applied pressure to a pre-marked trigger point using the thumb for 2 minutes until tissue resistance was felt. This included 60-second compression and after a break of a few seconds, another 60 seconds of compression. Therapies were performed on each side. Measurements were taken before and 2 minutes after the therapy.
Study NCT04836910 — intervention group
Intervention type: OTHER
Intervention: Dietary recommendations
Description: Fruit, vegetables, legumes (e.g. lentils and beans), nuts and whole grains (e.g. unprocessed maize, millet, oats, wheat and brown rice).~At least 400 g (i.e. five portions) of fruit and vegetables per day excluding potatoes, sweet potatoes, cassava and other starchy roots.~Less than 10% of total energy intake from free sugars Less than 30% of total energy intake from fats. Unsaturated fats (found in fish, avocado and nuts, and in sunflower, soybean, canola and olive oils) are preferable to saturated fats.~Less than 5 g of salt (equivalent to about one teaspoon) per day.
Study NCT04836910 — intervention group
Intervention type: DRUG
Intervention: Oral contraceptive pills
Description: Hormonal treatment
Study NCT04836910 — intervention group
Intervention type: DRUG
Intervention: Metformin
Description: Insulin resistance treatment
Study NCT05715346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEV102 1.0%
Description: Oxymetazoline ophthalmic gel
Study NCT05715346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEV102 2.0%
Description: Oxymetazoline ophthalmic gel
Study NCT05715346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle ophthalmic gel
Study NCT05060484 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCT1000
Description: HPV vaccine
Study NCT05060484 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil®9
Description: HPV vaccine
Study NCT05060484 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil®
Description: HPV vaccine
Study NCT05060484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: adjuvent
Study NCT06349200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 432 Hz music
Description: Music tuned to the 432 Hz frequency, as compared with other frequencies, has the advantage of providing utter calm, pleasure, and peace to its listeners. It has proven to be effective for reducing stress and improving sleep quality
Study NCT06349200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Binaural beats
Description: Binaural beats are defined as the sound that is born when two sounds of constant intensity but different frequencies are presented to both ears separately. The resultant sound perceived in the brain has a single tone and a frequency equivalent to the difference between the frequencies of the carrier sounds
Study NCT06349200 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: White noise
Description: White noise is a type of random sound characterized by equal intensity across all frequencies within the audible range, resulting in a steady, uniform sound similar to the static from a television or radio tuned to an unused frequency.
Study NCT05456945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure application
Description: Acupressure will be applied to the UB32 point
Study NCT05456945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shotblocher
Description: Shotblocher will be administered during injection
Study NCT04332198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biological test
Description: dyspnea evaluation, ventilatory evaluation and biological test before and after non invasive ventilation
Study NCT04848974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV
Study NCT04848974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given SC
Study NCT06553469 — intervention group
Intervention type: DEVICE
Intervention: sacral neuromodulation
Description: After screening according to the inclusion and exclusion criteria, the subjects were enrolled in the study. The sacral nerve regulation treatment was divided into two phases. Phase I was the testing phase, during which the sacral nerve stimulation electrode component was implanted. After the electrode was implanted, it was tested for 2-4 weeks. According to the urine diary and scale scores, if the symptoms improved by ≥ 50%, or if the patient requested to continue with Phase II and was evaluated by the researcher as suitable for implantation, Phase II (permanent implantation phase) treatment was performed, during which the sacral nerve stimulation pulse generator component was implanted
Study NCT04997421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes
Description: Combined HA380 hemoadsorption and continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (intervention arm)or mere CVVHDF using the Oxiris®-AN69 membrane (control arm).
Study NCT04997421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes
Description: Continuous veno-venous hemodiafiltration (CVVHDF) with Oxiris®-AN69 membranes (control arm)
Study NCT05152914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerliponase Alfa
Description: Brineura is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.
Study NCT06475651 — intervention group
Intervention type: GENETIC
Intervention: Methylation analysis
Description: Genomic DNA will be treated with bisulfite. 500 ng of processed DNA is then hybrized on an EPICv2 array Infinium methylation (Illumina, San Diego, CA, USA). This microarray enables the analysis of approximately 865 000 methylation sites at promoters, enhancers, CpG islands, intergenic and intragenic regions. It is the most widely used chip in the literature, including almost all of the EPIGENETIC SIGNATURES reported in human pathology.
Study NCT05022875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healthcare CEO app- for experimental app intervention
Description: The app content was designed based on the results of previous qualitative and Delphi studies (Chiang et al., 2021; Chiang et al., 2020) and consists of 11 interfaces: CEO's profile, Health Tracking, CEO Knowledge Base, Barrier-free Communication, See Here: Diet and Exercise, Help Me, Detective!, CEO Chatroom, CEO's Secretary, Who's the Best CEO, SOS Calls, and Q\&A
Study NCT05022875 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Healthcare CEO app-for control app intervention
Description: consists of 2 interfaces: CEO's profile, Health Tracking.
Study NCT06148389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1301 subcutaneous injection
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.
Study NCT06148389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.
Study NCT06268639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osseodensification
Description: The intervention, osseodensification, involves a surgical technique using specific drills (e.g., Densah burs) rotated in a counterclockwise direction to compact bone rather than remove it, thereby increasing bone density around the implant site. This method is aimed at improving the primary stability of dental implants by creating a denser bone environment, which theoretically should lead to better osseointegration and long-term success of the implant. The technique distinguishes itself from traditional drilling by preserving and enhancing bone structure, which is crucial for the success of dental implants in patients.
Study NCT04765865 — intervention group
Intervention type: OTHER
Intervention: SHAKE Package
Description: The SHAKE (Surveillance of salt intake, Harness industry, Adopt standards for labelling and marketing, Knowledge to empower consumers, and Environments to promote health eating) package is a WHO Best Buy and is recently implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC).
Study NCT04848974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: Given IV
Study NCT06304441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Double-dose of TKI (e.g. 'osimertinib' 160 mg) was administered orally once daily until disease progression or unmanageable drug-related toxicity.
Study NCT06304441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Double-dose of TKI (e.g. 'osimertinib' 160 mg) was administered orally once daily until disease progression or unmanageable drug-related toxicity.
Study NCT06304441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture. First, induction intrathecal chemotherapy, twice per week for 2 weeks; then consolidation intrathecal chemotherapy, once per week for 4 weeks; and maintenance intrathecal chemotherapy, once per month until disease progression or unmanageable drug-related toxicity.
Study NCT05921448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaxigripetra
Description: Tetravalent intramuscular vaccine. Mechanism of action: The vaccine induces an immune reaction involving antibody production.
Study NCT04828538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Daily 4000 IU Vitamin D for 60 days
Study NCT04828538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega DHA / EPA
Description: Daily 1000mg Omega DHA/EPA for 60 days
Study NCT04828538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C, Vitamin B complex and Zinc Acetate
Description: Combination 1000 mg Vitamin C, Vitamin B complex\*\* and Zinc Acetate, 100 mg/day for 60 days~\*\*(Vitamin B complex components: B12=1 mg; B6=50 mg; B9=2.5 mg; B1=100 mg; B2=100 mg; B3=14 mg; B7=50 mg)
Study NCT04828538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04934254 — intervention group
Intervention type: OTHER
Intervention: Attitude Scale
Description: 26-item related to scale will construct and apply to nurses for creating scale
Study NCT05380596 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telepharmaceutical Care
Description: The intervention will be carried out through three teleconsultations, one per month, with a pharmacist (Times 0, 1, 2 and 3). In the opportunities, aspects related to pharmacotherapy and health status, non-pharmacological approaches, treatment adherence and evaluation of problems related to pharmacotherapy (PRM) will be discussed.
Study NCT06404346 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High Velocity Thrust
Description: Group A Participants assigned to the HVT will receive manual therapy sessions consisting of specific manipulative techniques targeting the sacroiliac joint and surrounding structures. participant lying on your side or on your stomach, depending on which SI joint needs to be manipulated.The physiotherapist will stabilize body to isolate the specific SI joint that needs adjustment. This may involve holding certain parts of your body in place or using props like a belt or cushion.With precise control and speed, the physiotherapist will apply a sudden thrust to the targeted SI joint. This thrust aims to mobilize the joint and restore its normal function. This procedure will perform in 3 sessions per week for 2 weeks
Study NCT06404346 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bowen therapy
Description: participants will undergo sessions involving gentle, rolling movements over muscles, tendons, and ligaments in sacroiliac joint . participant lie comfortably on a treatment bed fully clothed, typically face down or on your side. The physiotherapist will perform a series of gentle, rolling movements with their fingers and thumbs over specific points on your body, including the lower back, hips, and buttocks. These moves are designed to stimulate the nervous system and promote relaxation and healing in the affected area.
Study NCT05640739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Demonstration method for the use of the Metered Dose Inhaler
Description: The effectiveness of the training given by the demonstration method for the use of the Metered Dose Inhaler (MDI)
Study NCT05640739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video watching method for the use of the Metered Dose Inhaler
Description: The effectiveness of the training given by video watching method for the use of the Metered Dose Inhaler (MDI)
Study NCT06223477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich Fibrin
Description: PRF will be injected distal to the canine on the experimental side.
Study NCT06223477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin Dꝫ will be injected distal to the canine on the experimental side
Study NCT06218836 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pre-inflated endotracheal tube
Description: The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Then, the cuff will be inflated to 40 cm of H2O to gain full stretch inflation.Thereafter the cuff will be deflated with the help of cuff inflator-deflator device to maintain intracuff pressure of 4 cm H2O The external cuff balloon will be obliterated with a soft clamp to ensure that at the time of passage of tube through the glottic-inlet, the tube cuff does not get deflated due to pressure equalization with the external balloon.
Study NCT06218836 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-inflated endotracheal tube
Description: The ETT (males: size 7.5 mm ID, females: size 6.5 mmID) will be taken out from the wrapper and submerged in 0.9% normal saline till the proximal margin of the cuff. Thereafter the endotracheal intubation will be done.
Study NCT06443385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDMP Legal Mandate E-mail
Description: E-mails highlighting the state's legal requirements to use the PDMP. There will be one initial email and one follow-up email one month later.
Study NCT06443385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PDMP Clinical Benefit E-mail
Description: E-mails highlighting the clinical benefits of having access to the PDMP and checking the PDMP before prescribing opioids. There will be one initial email and one follow-up email one month later.
Study NCT05266001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF
Description: same as arm/group description
Study NCT05266001 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same as arm/group description
Study NCT04295486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Non-enteric coated 81 mg Aspirin tablet.
Study NCT04295486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Non-enteric coated 81 mg Aspirin tablet.
Study NCT05602766 — intervention group
Intervention type: DRUG
Intervention: NGENLA (Somatrogon)
Description: Dosage, Frequency: Refer to the latest package insert.
Study NCT05752721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition to Online Ordering
Description: The intervention food pantry will transition to online ordering at least once.
Study NCT05680740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTAMA® (tapinarof) Cream 1%
Description: VTAMA® (tapinarof) Cream 1% applied topically once daily
Study NCT06468384 — intervention group
Intervention type: PROCEDURE
Intervention: thoracic erector spinae plane (ESP) block
Description: The thoracic erector spinae plane (ESP) block is a regional anesthesia technique used for pain management in complex regional pain syndrome. This procedure involves injecting 20 ml of 0.25% bupivacaine into the deep layers of the erector spinae muscles. The patient is positioned appropriately, and the injection site is identified using anatomical landmarks and ultrasound guidance, at the T2 level. A needle is then inserted perpendicularly until it contacts the transverse process, at which point the local anesthetic is administered. The primary objective is to provide significant pain relief.
Study NCT05852769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986196
Description: Specified dose on specified days
Study NCT05852769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Specified dose on specified days
Study NCT05886985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MatriPlax
Description: MatriPlax contains pcMSCs (placenta choriodecidual membrane-derived mesenchymal stem cells) and will be given intravenously on Day 1 and Day 4
Study NCT04562753 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maïa® TMC Prosthesis (Lépine Groupe)
Description: Patients undergoing thumb basal joint arthroplasty using Maïa® TMC prosthesis as treatment of osteoarthritis.
Study NCT05804292 — intervention group
Intervention type: OTHER
Intervention: Questionnaire administration
Description: Questionnaire administration
Study NCT06309797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interdental brush+HA
Description: interdental brushes (TePe Munhygienprodukter AB, Malmö; TePe 0.4 mm and TePe 0.6 mm) +20 mL of 0.2% HA gel (Gengigel; Ricerfarma, Milan, Italy)
Study NCT06309797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interdental brush
Description: interdental brushes (TePe Munhygienprodukter AB, Malmö; TePe 0.4 mm and TePe 0.6 mm)
Study NCT04562753 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: APL Suspensionplasty
Description: Patients undergoing thumb basal joint arthroplasty using APL Suspensionplasty as treatment of osteoarthritis.
Study NCT05852769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Specified dose on specified days
Study NCT05852769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Specified dose on specified days
Study NCT05852769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Specified dose on specified days
Study NCT04973189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707
Description: A single dose of SHR-1707 by intravenous (IV) infusion in healthy young adults.
Study NCT04973189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in healthy young adults.
Study NCT04973189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707
Description: A single dose of SHR-1707 by intravenous (IV) infusion in elderly subjects.
Study NCT04973189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in elderly subjects.
Study NCT04767308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT125A cells
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to manufacture CT125A cells, during which cyclophosphamide and fludarabine will be administered for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with CT125A cells by intravenous (IV) infusion. The initial dose of 1×10\^6 CAR+ T cells/kg will be infused on day 0.